Knee Replacement — Cost, Top Hospitals & Success Rates | MyMedicPlus

Total knee replacement (TKR), or total knee arthroplasty (TKA), is a surgical procedure that resur­faces the damaged articular surfaces of the knee joint — the distal femur, proximal tibia, and posterior patella — with metal alloy and high-density polyethylene components, restoring a smooth, pain-free articulating surface. The knee is the largest and most complex joint in the body; in advanced arthritis the protective cartilage completely erodes, causing bone-on-bone contact, severe pain, deformity (varus or valgus), and near-total loss of mobility. The prosthetic system consists of a cobalt-chromium femoral component, a tibial tray (titanium or cobalt-chrome) fixed to the tibial plateau, a cross-linked polyethylene insert seated between the metal components, and optionally a patellar resurfacing button. Fixation is achieved with bone cement (cemented), press-fit porous coating (cementless), or hybrid. Computer navigation systems and robotic-arm-assisted technology (such as Stryker Mako) enable individualised 3D pre-operative planning and sub-millimetre accuracy of bone resection, reducing alignment outliers. Unicompartmental (partial) knee replacement resurfaces only the medial or lateral compartment when disease is isolated. Surgery takes 1–2 hours under spinal or general anaesthesia. Enhanced Recovery After Surgery (ERAS) protocols now enable many patients to walk on the day of surgery and discharge within 1–3 days.

Total knee replacement is primarily performed for end-stage osteoarthritis of the knee — the most common indication — characterised by progressive cartilage loss, subchondral sclerosis, osteophyte formation, and joint space obliteration on standing radiographs. Other major indications include rheumatoid arthritis and other inflammatory arthropathies (psoriatic arthritis, reactive arthritis, lupus arthritis) that destroy joint cartilage via synovial inflammation; post-traumatic arthritis following tibial plateau or distal femoral fractures, ligamentous disruption, or meniscal damage leading to compartment collapse; avascular necrosis of the femoral condyle or tibial plateau; severe crystal arthropathy (gout or calcium pyrophosphate deposition disease) causing destructive joint changes; and haemophilic arthropathy from recurrent haemarthroses. Unicompartmental knee replacement addresses isolated medial compartment osteoarthritis (most common, ~75% of unicompartmental cases), isolated lateral compartment disease, or patellofemoral arthritis. Revision TKR is performed when primary implants fail due to aseptic loosening, polyethylene wear, periprosthetic joint infection, instability, flexion contracture, or stiffness unresponsive to rehabilitation.

Knee replacement is recommended when severe knee pain substantially limits daily activities — walking more than one city block, ascending or descending stairs, rising from a chair, or disrupting sleep — and conservative management for 6 months has failed. Conservative measures include NSAIDs, tramadol, physiotherapy, quadriceps strengthening, corticosteroid injections (maximum 3–4 per year), hyaluronic acid injections, and structured weight loss. Radiographic evidence on standing AP and lateral X-rays must confirm significant joint space narrowing, subchondral sclerosis, or osteophytes consistent with Grade 3–4 Kellgren-Lawrence arthritic change. Pre-operative evaluation includes lower-limb alignment X-rays (full-length EOS or long leg views), blood tests (FBC, ESR, CRP, HbA1c, coagulation profile), cardiac clearance, urinalysis to exclude urinary tract infection, and dental review. Optimal candidates are aged 60–80 with BMI under 40. Younger patients (40–60) with severe post-traumatic or inflammatory arthritis may undergo TKR with the expectation of one revision in their lifetime. Absolute contraindications include active periprosthetic or systemic infection, absent or non-functional quadriceps muscle, vascular insufficiency of the limb, or severe neuromuscular disease. Optimisation of HbA1c below 8%, haemoglobin above 120 g/L, BMI ideally below 35, and smoking cessation at least 6 weeks pre-operatively are strongly recommended to reduce complication risk.

Treatment options are tailored to individual patient needs based on disease severity, comorbidities, patient preference, and clinical guidelines. The treating physician will discuss all available options and recommend an approach based on the complete clinical assessment.

First-line treatment follows established evidence-based protocols with well-documented efficacy and safety profiles. This may involve pharmacological therapy with single or combination agents, procedural intervention using minimally invasive or open techniques, or a combination approach integrating multiple treatment modalities.

Second-line options are considered when primary treatment fails to achieve therapeutic targets or is not tolerated. These include alternative agents within the same drug class, different treatment modalities, or escalation to more intensive therapy at specialist centres.

Emerging treatments available through clinical trials or specialist referral include novel targeted agents, biological therapies, advanced procedural techniques, and gene therapy approaches for selected conditions. Patients are encouraged to discuss eligibility for clinical trials with their specialist. Treatment intensity is regularly reassessed and adjusted based on clinical response, ensuring optimal outcomes while minimising unnecessary exposure to treatment-related risks.

The selection of treatment approach follows a systematic assessment of clinical factors, patient preferences, and risk-benefit considerations. Evidence-based guidelines from professional societies including WHO, NICE, and relevant specialty organisations inform treatment selection and protocol design.

Combination treatment strategies are increasingly favoured where multiple modalities provide synergistic benefit. The sequence and intensity of treatment components are titrated based on patient response at defined assessment intervals. Patients not responding adequately to initial treatment undergo structured reassessment to identify alternative approaches or combination strategies.

Personalised medicine approaches using biomarker profiling and genetic analysis are emerging as tools to predict treatment response and guide individualised treatment selection in eligible patients. Multidisciplinary team review ensures all relevant clinical expertise informs treatment decisions for complex cases.

Total knee replacement reliably eliminates severe arthritic pain and restores functional mobility in over 90% of patients. National joint registry data demonstrates implant survival of 93–96% at 15 years and approximately 82–85% at 25 years. Patient satisfaction rates exceed 85% at 5-year follow-up when appropriately selected. Functional benefits include pain-free walking, ability to climb stairs, drive, sleep through the night, and participate in low-impact activities (swimming, cycling, golf, walking). ERAS protocols and minimally invasive approaches reduce blood loss, post-operative pain, and hospital stay to 1–3 days. Robotic-assisted surgery (Mako system) delivers sub-millimetre implant positioning accuracy and reduces soft-tissue damage. Bilateral simultaneous knee replacement (both knees in one anaesthetic) is an option for selected patients, saving total recovery time and cost. Unicompartmental replacement offers faster rehabilitation (4–6 weeks versus 3 months for TKR), better post-operative range of motion, preserved bone stock, and more natural joint feel, though it has somewhat higher long-term revision rates. Registry data consistently shows TKR produces clinically meaningful improvement in pain, function, and quality of life metrics.

Periprosthetic joint infection (PJI) is the most serious complication at 1–2% for primary and 3–5% for revision, often requiring two-stage explantation and reimplantation with 6 weeks of intravenous antibiotics. Deep vein thrombosis occurs in 1–5% despite pharmacological (LMWH, aspirin, rivaroxaban) and mechanical (compression stockings, sequential compression devices) prophylaxis; pulmonary embolism occurs in 0.1–0.3%. Aseptic loosening — mechanical failure without infection — affects 1–5% of implants at 10–15 years, the leading cause of late revision. Stiffness requiring manipulation under anaesthesia (MUA) affects 5–10% and is associated with pre-operative stiffness, suboptimal implant sizing, or inadequate rehabilitation. Persistent anterior knee pain in the region of the patella affects 5–15% of patients, more common when the patella is not resurfaced. Periprosthetic fracture affects 0.3–2%. Nerve injury (peroneal palsy causing foot drop) occurs in 0.3–1%. Wound healing complications, more frequent in diabetics and obese patients, may lead to dehiscence or superficial infection (2–4%). Implant malposition causes pain, instability, polyethylene wear, and early revision. Patient dissatisfaction affects approximately 15–20%, predominantly from persistent pain or unmet functional expectations, making pre-operative patient selection and expectation-setting critical.

Structured follow-up is essential to optimise treatment outcomes and ensure early identification of complications or disease recurrence. The follow-up schedule is individuialised based on treatment type, disease characteristics, and patient-specific factors.

Standard follow-up scheduling involves: early post-treatment review at 2-4 weeks to assess initial response and manage any early side effects; monthly assessments for the first 3 months to monitor treatment response and titrate therapy as needed; quarterly review for the remainder of the first year; and annual long-term follow-up for stable patients.

Each follow-up visit includes clinical examination, relevant laboratory testing as indicated by the treatment protocol, imaging studies at defined intervals based on condition-specific guidelines, and assessment of patient-reported outcomes and quality of life.

Patients are provided with clear guidance on symptoms requiring urgent medical review between scheduled appointments, including signs of serious complications or disease progression. Remote consultation options including telephone and video review facilitate access to specialist advice between face-to-face appointments. Long-term surveillance continues indefinitely for chronic conditions, with frequency adjusted based on individual risk profile and clinical response.

Knee replacement surgery in India costs USD 4,000–7,500 at leading JCI-accredited hospitals (Apollo, Fortis, Medanta, Max, Kokilaben Dhirubhai Ambani), inclusive of cemented or cementless implants from approved manufacturers (Zimmer Biomet, Stryker, DePuy Synthes, Smith & Nephew), surgeon and anaesthesia fees, 4–5 days hospitalisation, and initial physiotherapy sessions. Robotic-assisted (Mako) knee replacement in India adds USD 1,000–2,000, yielding a total of USD 5,500–9,000 — still 75–80% below comparable US costs. Bilateral simultaneous knee replacement in India costs USD 7,000–12,000, offering significant savings versus two separate procedures. In Thailand costs are USD 9,000–16,000; Turkey USD 6,000–12,000; Mexico USD 7,000–12,000; Singapore USD 15,000–28,000. In the USA, total knee replacement costs USD 35,000–70,000 without insurance; UK private hospitals charge GBP 13,000–22,000. International patient packages at major Indian hospitals include comprehensive pre-operative workup, physiotherapy, tele-follow-up appointments, and coordination with international insurers.

Alternative treatment approaches are considered when first-line treatment is contraindicated, not tolerated, or fails to achieve therapeutic targets. The range of alternatives depends on the specific condition and patient circumstances.

Conservative management with watchful waiting and close monitoring is appropriate for mild or asymptomatic presentations where the natural history is favourable and intervention risks outweigh expected benefits. Regular surveillance allows timely escalation when clinical criteria for active treatment are met.

Non-pharmacological approaches including physiotherapy, occupational therapy, dietary optimisation, and structured lifestyle modification programmes form the foundation of management for many conditions. These interventions reduce symptom burden, improve functional capacity, and may delay or eliminate the need for pharmacological or procedural treatment.

Alternative pharmacological approaches include agents from different drug classes with different mechanisms of action, dosing strategies, or delivery routes. Clinical trials evaluating novel agents may offer access to emerging therapies not yet in routine clinical practice.

Surgical alternatives range from minimally invasive endoscopic or laparoscopic approaches to open surgery, each appropriate for different clinical scenarios. Complementary and integrative medicine approaches including acupuncture, herbal medicine, and mind-body therapies may provide symptomatic benefit for some patients as adjuncts to conventional care, though evidence quality varies and potential interactions with conventional treatment should be discussed with a qualified practitioner.